Merck To High Court: FDA Rejected Warning About Drug’s Fracture Risk
WASHINGTON, D.C. — Merck Sharp & Dohme Corp. on Sept. 13 filed its opening brief asking the U.S. Supreme Court to find that the Food and Drug Administration considered and rejected...To view the full article, register now.
Already a subscriber? Click here to view full article